Unnamed: 0,title,date,stock,sentiment
1040046.0,PTC Therapeutics Files Prospectus Relates To Resales Of 2.8M Shares Of Its Common Stock By Selling Shareholders,2020-05-07 08:56:00-04:00,PTCT,positive
1040047.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,PTCT,negative
1040048.0,PTC Therapeutics To Acquire Censa Pharmaceuticals For $10M Upfront And Up To 850K Shares Of PTC Common Stock,2020-05-06 17:12:00-04:00,PTCT,positive
1040049.0,PTC Therapeutics to Acquire Censa Pharmaceuticals; PTC Will Pay An Upfront Consideration Of Approximately $10M In Cash And Up To 850K Shares Of PTC Common Stock,2020-05-06 17:12:00-04:00,PTCT,positive
1040050.0,"SunTrust Robinson Humphrey Maintains Buy on PTC Therapeutics, Lowers Price Target to $75",2020-05-01 13:03:00-04:00,PTCT,negative
1040051.0,"PTC Therapeutics Q1 EPS $(1.810) Misses $(1.310) Estimate, Sales $68.259M Miss $81.940M Estimate",2020-04-30 16:06:00-04:00,PTCT,negative
1040052.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,PTCT,positive
1040053.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,PTCT,neutral
1040054.0,PTC Therapeutics Announced Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy,2020-04-28 05:35:00-04:00,PTCT,negative
1040055.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,PTCT,negative
1040056.0,Citigroup Upgrades PTC Therapeutics to Buy,2020-04-09 05:19:00-04:00,PTCT,neutral
1040057.0,"Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Lowers Price Target to $85",2020-04-08 11:56:00-04:00,PTCT,negative
1040058.0,"PTC Therapeutics Reports FDA Extended PDUFA Date For Its Review Of Risdiplam New Drug Application To Aug. 24, 2020",2020-04-07 16:07:00-04:00,PTCT,neutral
1040059.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,PTCT,positive
1040060.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PTCT,neutral
1040061.0,"Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Raises Price Target to $86",2020-03-03 06:36:00-05:00,PTCT,negative
1040062.0,PTC Therapeutics Q4 Sales $96.459M Beat $95.24M Estimate,2020-03-02 16:07:00-05:00,PTCT,neutral
1040063.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,PTCT,neutral
1040064.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,PTCT,negative
1040065.0,"RBC Capital Downgrades PTC Therapeutics to Sector Perform, Lowers Price Target to $60",2020-02-20 05:12:00-05:00,PTCT,negative
1040066.0,"Citigroup Downgrades PTC Therapeutics to Neutral, Raises Price Target to $71",2020-02-20 05:08:00-05:00,PTCT,neutral
1040067.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,PTCT,negative
1040068.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,PTCT,negative
1040069.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,PTCT,neutral
1040070.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,PTCT,positive
1040071.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,PTCT,neutral
1040072.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,PTCT,positive
1040073.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,PTCT,negative
1040074.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,PTCT,negative
1040075.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,PTCT,neutral
1040076.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,PTCT,neutral
1040077.0,PTC Therapeutics Highlights First Publication Of Data Showing Translarnaä 'Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy',2020-02-03 08:04:00-05:00,PTCT,positive
1040078.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,PTCT,neutral
1040079.0,"UPDATE: Cantor Fitzgerald On PTC Therapeutics Is 'confident in a May approval or earlier based on the data generated between FIREFISH and SUNFISH, and we think that an oral medicine is a game changer in this population taking intrathecal injections'",2020-01-23 11:13:00-05:00,PTCT,positive
1040080.0,"UPDATE: Cantor Fitzgerald Maintains Overweight On PTC Therapeutics, Raises Target To $81 As Firm Notes 'Risdiplam will be a blockbuster' Adjusts 'PoS for risdiplam to 100% from 75% and factored in the milestones in the coming years'",2020-01-23 11:13:00-05:00,PTCT,positive
1040081.0,"Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $81",2020-01-23 11:05:00-05:00,PTCT,negative
1040082.0,Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy,2020-01-23 04:58:00-05:00,PTCT,positive
1040083.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,PTCT,neutral
1040084.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,PTCT,neutral
1040085.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,PTCT,negative
1040086.0,"PTC Therapeutics Sees 2020 Duchenne Franchise Revenue $320M-$340M, Provides Corporate Update",2020-01-13 08:29:00-05:00,PTCT,neutral
1040087.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,PTCT,positive
1040088.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,PTCT,neutral
1040089.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,PTCT,positive
1040090.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,PTCT,positive
1040091.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,PTCT,neutral
1040092.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,PTCT,positive
1040093.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,PTCT,neutral
1040094.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,PTCT,negative
1040095.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-03 10:13:00-05:00,PTCT,neutral
1040096.0,PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy,2019-11-25 05:19:00-05:00,PTCT,positive
1040097.0,"Credit Suisse Maintains Outperform on PTC Therapeutics, Raises Price Target to $58",2019-11-13 08:19:00-05:00,PTCT,positive
1040098.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,PTCT,positive
1040099.0,"SunTrust Robinson Humphrey Initiates Coverage On PTC Therapeutics with Buy Rating, Announces $78 Price Target",2019-11-12 06:31:00-05:00,PTCT,neutral
1040100.0,20 Stocks Moving in Monday's Pre-Market Session,2019-11-11 07:40:00-05:00,PTCT,neutral
1040101.0,PTC Therapeutics Announces Risdiplam Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy,2019-11-11 04:07:00-05:00,PTCT,positive
1040102.0,"Citigroup Maintains Buy on PTC Therapeutics, Lowers Price Target to $55",2019-10-30 07:57:00-04:00,PTCT,negative
1040103.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,PTCT,negative
1040104.0,"PTC Therapeutics Q3 EPS $(1.06) Misses $(0.76) Estimate, Sales $71.4M Miss $73.02M Estimate",2019-10-29 16:14:00-04:00,PTCT,negative
1040105.0,PTC Therapeutics Offers Results From Long-Term AADC Deficiency Gene Therapy Treatment Showing Sustained Improvements,2019-10-24 08:15:00-04:00,PTCT,positive
1040106.0,PTC Therapeutics Highlights Analysis Showing Translarna™ Slows Disease Progression in Patients with Duchenne Muscular Dystrophy,2019-10-04 08:02:00-04:00,PTCT,neutral
1040107.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,PTCT,neutral
1040108.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,PTCT,negative
1040109.0,52 Biggest Movers From Yesterday,2019-09-19 05:18:00-04:00,PTCT,neutral
1040110.0,36 Stocks Moving In Wednesday's Mid-Day Session,2019-09-18 13:19:00-04:00,PTCT,neutral
1040111.0,PTC Therapeutics Prices ~2.475M Share Common Stock Offering At $40.40/Share,2019-09-18 08:27:00-04:00,PTCT,positive
1040112.0,PTC Therapeutics shares are trading lower after the company reported a $100 million common stock offering.,2019-09-18 08:22:00-04:00,PTCT,neutral
1040113.0,10 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-18 08:13:00-04:00,PTCT,neutral
1040114.0,30 Stocks Moving in Wednesday's Pre-Market Session,2019-09-18 07:52:00-04:00,PTCT,neutral
1040115.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,PTCT,neutral
1040116.0,PTC Therapeutics shares are trading lower after the company reported a $100 million common stock offering.,2019-09-17 16:17:00-04:00,PTCT,neutral
1040117.0,PTC Therapeutics Reports $100M Common Stock Offering,2019-09-17 16:15:00-04:00,PTCT,neutral
1040118.0,"PTC Therapeutics Q2 EPS $(0.75) Misses $(0.58) Estimate, Sales $85.522M Beat $78.64M Estimate",2019-08-06 16:20:00-04:00,PTCT,negative
1040119.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,PTCT,positive
1040120.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,PTCT,neutral
1040121.0,PTC Therapeutics Option Alert: Dec 20 $50 Calls at the Ask: 4000 @ $4.1 vs 9 OI; Earnings 8/6 After Close [est] Ref=$44.04,2019-07-08 11:46:00-04:00,PTCT,positive
1040122.0,"PTC Therapeutics Announces Gene Therapy Licensing Agreement with Odylia Therapeutics, Terms Not Disclosed",2019-07-01 08:09:00-04:00,PTCT,positive
1040123.0,28 Stocks Moving In Friday's Pre-Market Session,2019-06-28 08:13:00-04:00,PTCT,neutral
1040124.0,"UPDATE: PTC Says Plans To Request Reexamination Of Procedure Within Next 2 Weeks, Sees New Examination Lasting ~4 Months",2019-06-28 06:42:00-04:00,PTCT,neutral
1040125.0,PTC Therapeutics Reports Negative EMA's CHMP Completed Review Of Proposed Indication Extension For Translarna; Co. Was Informed EMA Reps That EPAR Will Be Updated To Clarify Patients Who Start Translarna Not Required To Discontinue Treatment,2019-06-28 06:42:00-04:00,PTCT,negative
1040126.0,PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients,2019-06-07 15:02:00-04:00,PTCT,positive
1040127.0,PTC Therapeutics Reports FDA Approval For Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age,2019-06-07 13:33:00-04:00,PTCT,positive
1040128.0,"PTC Therapeutics Shares Tick Lower Here As Traders Circulate Word RBC Capital Out Positive On Stock, CitedA ClinicalTrials.gov Record For Co.'s AVXS-101",2019-05-20 14:49:00-04:00,PTCT,positive
1040129.0,10 Biggest Price Target Changes For Monday,2019-05-13 09:42:00-04:00,PTCT,neutral
1040130.0,"Bank of America Upgrades PTC Therapeutics, Inc. - Common Stock to Buy, Raises Price Target to $49",2019-05-13 08:00:00-04:00,PTCT,neutral
1040131.0,PTC Therapeutics Announces $4M Investment in MRI Interventions,2019-05-09 17:28:00-04:00,PTCT,neutral
1040132.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,PTCT,neutral
1040133.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,PTCT,neutral
1040134.0,"PTC Therapeutics Q1 EPS $(1.29) Misses $(0.73) Estimate, Sales $53.6M Miss $70.01M Estimate",2019-05-02 17:14:00-04:00,PTCT,negative
1040135.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,PTCT,positive
1040136.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,PTCT,negative
1040137.0,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",2019-04-11 09:09:00-04:00,PTCT,positive
1040138.0,"Bernstein Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces $48 Price Target",2019-04-11 07:27:00-04:00,PTCT,neutral
1040139.0,"Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds",2019-04-10 09:59:00-04:00,PTCT,neutral
1040140.0,"PTC Therapeutics Sees FY19 Net Product Revenues $285M-$305M, Sees Adj. R&D And SG&A Expense $360M-$370M",2019-02-28 16:54:00-05:00,PTCT,neutral
1040141.0,"PTC Therapeutics Q4 EPS $(0.96) Misses $(0.33) Estimate, Sales $86.34M Beat $84.61M Estimate",2019-02-28 16:52:00-05:00,PTCT,negative
1040142.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,PTCT,positive
1040143.0,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,2019-02-25 15:12:00-05:00,PTCT,positive
1040144.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,PTCT,neutral
1040145.0,54 Biggest Movers From Yesterday,2019-01-24 05:04:00-05:00,PTCT,neutral
1040146.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-01-23 12:27:00-05:00,PTCT,neutral
1040147.0,PTC Therapeutics shares are trading lower after the company announced a 6.72 share common stock offering at $30.20 per share.,2019-01-23 10:32:00-05:00,PTCT,positive
1040148.0,PTC Therapeutics Prices 6.72M Share Common Stock Offering At $30.20/Share,2019-01-23 08:55:00-05:00,PTCT,positive
1040149.0,28 Stocks Moving In Wednesday's Pre-Market Session,2019-01-23 08:01:00-05:00,PTCT,neutral
1040150.0,"The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study",2019-01-23 07:22:00-05:00,PTCT,positive
1040151.0,PTC Therapeutics Reports $200M Common Stock Offering,2019-01-22 16:09:00-05:00,PTCT,neutral
1040152.0,PTC Therapeutics Sees FY19 Sales $285M-$305M May Not Compare To $348.9M Est.,2019-01-07 08:18:00-05:00,PTCT,neutral
1040153.0,PTC Therapeutics Provides Corporate Update And Outlines 5-year Strategic Plan At 2019 J.P. Morgan Healthcare Conference,2019-01-07 08:17:00-05:00,PTCT,neutral
1040154.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,PTCT,positive
1040155.0,PTC Narrows FY18 Product Sales Guidance From $260M-$295M To $260M-$280M,2018-11-05 16:46:00-05:00,PTCT,neutral
1040156.0,"PTC Therapeutics Q3 EPS $(1.06) Misses $(0.40) Estimate, Sales $53.591M Miss $70.9M Estimate",2018-11-05 16:45:00-05:00,PTCT,negative
1040157.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,PTCT,neutral
1040158.0,PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation,2018-10-07 07:35:00-04:00,PTCT,negative
1040159.0,PTC Therapeutics Shares Spike Over $46 Level To Session High As Hearing BofA Upgraded Stock Midday; Shares Up 3.9% For Session,2018-10-03 14:13:00-04:00,PTCT,positive
1040160.0,"Traders Circulate Comment From JP Morgan On PTC Therapeutics: 'Solid Updates for Risdi at WMS. Near-term Buying Opp'y on Unfounded Weakness'; PTC Shares Down 3% For Session, But Up ~16% From Session Low Just After Open",2018-10-03 11:33:00-04:00,PTCT,neutral
1040161.0,"Risdiplam Demonstrates Preliminary Evidence Of Clinical Benefit In Type 1, 2, & 3 Spinal Muscular Atrophy Patients; Patients Showed Increase In Survival And Increase In Motor Function",2018-10-03 07:36:00-04:00,PTCT,positive
1040162.0,"Cantor Fitzgerald Initiates Coverage On PTC Therapeutics with Overweight Rating, Announces $66 Price Target",2018-10-01 08:17:00-04:00,PTCT,negative
1040163.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-30 10:14:00-04:00,PTCT,neutral
1040164.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,PTCT,neutral
1040165.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,PTCT,positive
1040166.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,PTCT,positive
1040167.0,PTC Therapeutics Reaffirms FY18 Sales Guidance $260M-$295M vs $271.8M Estimate,2018-08-07 16:03:00-04:00,PTCT,neutral
1040168.0,"PTC Therapeutics, Inc. - Common Stock Q2 EPS $(0.21) Beats $(0.30) Estimate, Sales $68.743M Beat $65.7M Estimate",2018-08-07 16:02:00-04:00,PTCT,neutral
1040169.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,PTCT,negative
1040170.0,"Akcea Therapeutics, PTC Therapeutics Partner to Commercialize Two Rare Disease Drugs in Latin America; PTC To Gain Exclusive Rights To TEGSEDI and WAYLIVRA In These Areas And Akcea To Receive Licensing Fee Of $18M",2018-08-02 08:15:00-04:00,PTCT,positive
1040171.0,"PTC Therapeutics Reports Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort, Says delazacort Had Notably Less Decline From Baseline In 6-Minute Walk Distance At Week 48 vs Those Treated With prednisone/prednisolone",2018-07-24 08:11:00-04:00,PTCT,positive
1040172.0,"Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $50",2018-07-24 07:57:00-04:00,PTCT,neutral
1040173.0,41 Biggest Movers From Friday,2018-07-23 04:04:00-04:00,PTCT,neutral
1040174.0,31 Stocks Moving In Friday's Mid-Day Session,2018-07-20 12:51:00-04:00,PTCT,neutral
1040175.0,Mid-Morning Market Update: Markets Mostly Flat; Honeywell Tops Q2 Expectations,2018-07-20 10:11:00-04:00,PTCT,positive
1040176.0,32 Stocks Moving In Friday's Pre-Market Session,2018-07-20 08:14:00-04:00,PTCT,neutral
1040177.0,"Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2",2018-07-20 07:53:00-04:00,PTCT,positive
1040178.0,"10 Stocks To Watch For July 20, 2018",2018-07-20 04:56:00-04:00,PTCT,neutral
1040179.0,6 Stocks Moving In Thursday's After-Hours Session,2018-07-19 17:22:00-04:00,PTCT,neutral
1040180.0,"PTC Therapeutics Shares Resume Trade, Now Up 6.5%",2018-07-19 16:40:00-04:00,PTCT,positive
1040181.0,PTC Therapeutics Shares To Resume At 4:40 p.m. EDT,2018-07-19 16:14:00-04:00,PTCT,positive
1040182.0,"PTC Therapeutics To Acquire Agilis Biotherapeutics For $50M Cash and $150M In Common Stock With Potential Future $60M In Milestone Payments, With An Add'l $535M In Regulatory Approval Milestone Payments and $150M In Tiered Commercial Milestones of $150M",2018-07-19 16:12:00-04:00,PTCT,positive
1040183.0,PTC Therapeutics Shares Halted News Pending,2018-07-19 16:00:00-04:00,PTCT,positive
1040184.0,"Benzinga's Top Upgrades, Downgrades For July 19, 2018",2018-07-19 09:05:00-04:00,PTCT,positive
1040185.0,"Credit Suisse Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces $49 Price Target",2018-07-19 08:21:00-04:00,PTCT,positive
1040186.0,PTC Therapeutics Reports Data from its Translarna Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy,2018-07-09 08:02:00-04:00,PTCT,negative
1040187.0,"Benzinga's Top Upgrades, Downgrades For June 20, 2018",2018-06-20 09:20:00-04:00,PTCT,positive
1040188.0,The Market In 5 Minutes: Walgreens To Replace GE In The Dow Jones Industrial Average,2018-06-20 09:01:00-04:00,PTCT,neutral
1040189.0,Barclays Upgrades PTC Therapeutics to Equal-Weight,2018-06-20 06:17:00-04:00,PTCT,neutral
1040190.0,48 Biggest Movers From Yesterday,2018-06-20 03:55:00-04:00,PTCT,neutral
1040191.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Sarepta Shares Spike Higher,2018-06-19 15:04:00-04:00,PTCT,negative
1040192.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-06-19 13:44:00-04:00,PTCT,neutral
1040193.0,Mid-Day Market Update: Dow Down 350 Points; Tellurian Shares Plunge,2018-06-19 12:56:00-04:00,PTCT,positive
1040194.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jun. 19, 2018",2018-06-19 12:27:00-04:00,PTCT,positive
1040195.0,"Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares",2018-06-19 08:08:00-04:00,PTCT,positive
1040196.0,60 Biggest Movers From Yesterday,2018-06-19 04:02:00-04:00,PTCT,neutral
1040197.0,William Blair Upgrades PTC Therapeutics On Risdiplam Prospects,2018-06-18 12:48:00-04:00,PTCT,positive
1040198.0,42 Stocks Moving In Monday's Mid-Day Session,2018-06-18 12:28:00-04:00,PTCT,neutral
1040199.0,PTC Therapeutics Option Alert: Sep 21 $50 Calls Sweep (2) near the midpoint: 1439 @ $4.0 vs 0 OI; Earnings 8/7 After Close [est] Ref=$48.234,2018-06-18 12:11:00-04:00,PTCT,positive
1040200.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Jun. 18, 2018",2018-06-18 10:53:00-04:00,PTCT,positive
1040201.0,Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share,2018-06-18 10:18:00-04:00,PTCT,negative
1040202.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-18 09:11:00-04:00,PTCT,neutral
1040203.0,"Benzinga's Top Upgrades, Downgrades For June 18, 2018",2018-06-18 09:10:00-04:00,PTCT,positive
1040204.0,"The Market In 5 Minutes: China, OPEC, Banks, Bitcoin And More",2018-06-18 09:00:00-04:00,PTCT,neutral
1040205.0,PTC Therapeutics Shares Up 37.2% Premarket After Co. On Saturday Reported Positive Risdiplam (RG7916) In Babies With Type 1 Spinal Muscular Atrophy,2018-06-18 08:53:00-04:00,PTCT,positive
1040206.0,26 Stocks Moving In Monday's Pre-Market Session,2018-06-18 08:23:00-04:00,PTCT,neutral
1040207.0,William Blair Upgrades PTC Therapeutics to Outperform,2018-06-18 07:28:00-04:00,PTCT,neutral
1040208.0,RBC Capital Upgrades PTC Therapeutics to Outperform,2018-06-18 06:16:00-04:00,PTCT,neutral
1040209.0,PTC Therapeutics Announces Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference,2018-06-16 15:02:00-04:00,PTCT,neutral
1040210.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,PTCT,positive
1040211.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,PTCT,neutral
1040212.0,PTC Therapeutics Reports CHMP Adopted Positive Opinion For Expansion Of Translarna Label To Include Patients As Young As 2 Years Of Age,2018-06-01 07:45:00-04:00,PTCT,positive
1040213.0,"PTC Therapeutics Q1 EPS $(0.46) Misses $(0.28) Estimate, Sales $56.062M Miss $64.75M Estimate",2018-05-09 16:40:00-04:00,PTCT,negative
1040214.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,PTCT,neutral
1040215.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,PTCT,neutral
1040216.0,PTC Therapeutic Announces Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at #AAN2018,2018-04-24 20:55:00-04:00,PTCT,neutral
1040217.0,"Benzinga's Top Upgrades, Downgrades For April 4, 2018",2018-04-04 09:45:00-04:00,PTCT,positive
1040218.0,"The Market In 5 Minutes: China Tariffs, Zuckerberg, Spotify, Model 3 Deliveries And More",2018-04-04 09:00:00-04:00,PTCT,neutral
1040219.0,"PTC Therapeutics, CHDI Foundation Announce a Partnership on a Small-Molecule Therapeutic for Huntington's Disease",2018-04-04 08:02:00-04:00,PTCT,neutral
1040220.0,Barclays Downgrades PTC Therapeutics to Underweight,2018-04-04 06:54:00-04:00,PTCT,neutral
1040221.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-03-29 08:22:00-04:00,PTCT,neutral
1040222.0,40 Biggest Movers From Yesterday,2018-03-29 05:08:00-04:00,PTCT,neutral
1040223.0,PTC Therapeutics Prices 4M Share Public Offering of Common Stock @$27.04/Share,2018-03-29 04:17:00-04:00,PTCT,positive
1040224.0,32 Stocks Moving In Wednesday's Mid-Day Session,2018-03-28 12:45:00-04:00,PTCT,neutral
1040225.0,PTC Therapeutics Shares Down 12.9% After Co. Tuesday Announced 4M Share Common Stock Offering,2018-03-28 11:07:00-04:00,PTCT,positive
1040226.0,PTC Therapeutics Announces 4M Share Common Stock Offering,2018-03-27 16:05:00-04:00,PTCT,positive
1040227.0,41 Biggest Movers From Yesterday,2018-03-08 04:46:00-05:00,PTCT,neutral
1040228.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-03-07 12:29:00-05:00,PTCT,neutral
1040229.0,PTC Therapeutics Sees FY18 Net Product Sales $260M-$295M,2018-03-06 16:20:00-05:00,PTCT,neutral
1040230.0,"PTC Therapeutics Reports Q4 EPS $0.03 vs $(0.78) In Same Qtr. Last Year, Sales $78.03M vs $74.4M Est.",2018-03-06 16:20:00-05:00,PTCT,neutral
1040231.0,PTC Therapeutics Q4 Earnings Preview,2018-03-06 08:05:00-05:00,PTCT,neutral
1040232.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,PTCT,neutral
1040233.0,FDA Reiterates Its Prior Decision On PTC's Appeal Of The CRL In Relation To The New Drug Application For ataluren,2018-02-20 08:04:00-05:00,PTCT,neutral
1040234.0,PTC Therapeutics Reports Launch Of 4th Annual STRIVE Grant Award Program For DMD,2018-02-13 08:11:00-05:00,PTCT,positive
1040235.0,PTC Therapeutics Sees FY18 Net Product Sales $260M-$295M vs $217.5M Est.,2018-01-08 08:29:00-05:00,PTCT,neutral
1040236.0,PTC Therapeutics Sees FY17 Sales ~$195M vs $181.5M Est.,2018-01-08 08:29:00-05:00,PTCT,neutral
1040237.0,"The Market In 5 Minutes: Low Floats, Ron Johnson, And Jobless Claims",2017-11-16 08:36:00-05:00,PTCT,negative
1040238.0,JP Morgan Upgrades PTC Therapeutics to Neutral,2017-11-16 06:11:00-05:00,PTCT,positive
1040239.0,"PTC Therapeutics Sees FY17 Translarna Sales $120M-$140M, EMFLAZA Sales From $15M-$20M to $20M-$25M, Total Sales From $155M-$180M to $160M-$185M vs $173.38M Est.",2017-11-02 16:56:00-04:00,PTCT,neutral
1040240.0,"PTC Therapeutics Reports Q3 EPS $(0.82) vs $(0.60) Est., Sales $41.853M vs $45.03M Est.",2017-11-02 16:54:00-04:00,PTCT,neutral
1040241.0,Bank of America Downgrades PTC Therapeutics to Underperform,2017-10-26 09:21:00-04:00,PTCT,neutral
1040242.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-26 08:06:00-04:00,PTCT,neutral
1040243.0,PTC Therapeutics Shares Now Up 5% Following Resumption Of Trade,2017-10-25 12:40:00-04:00,PTCT,positive
1040244.0,"PTC Therapeutics Shares Resume Trade, Now Up ~2%",2017-10-25 12:35:00-04:00,PTCT,positive
1040245.0,PTC Therapeutics To Open 12:35 p.m.,2017-10-25 12:21:00-04:00,PTCT,neutral
1040246.0,PTC Therapeutics Receives Complete Response Letter For Ataluren's NDA,2017-10-25 12:15:00-04:00,PTCT,neutral
1040247.0,PTC Therapeutics Halted Pending News,2017-10-25 11:05:00-04:00,PTCT,neutral
1040248.0,Benzinga's Option Alert Recap From October 24,2017-10-24 16:39:00-04:00,PTCT,positive
1040249.0,PTC Therapeutics Option Alert: Nov 17 $20 Calls Sweep (17) at the Ask: 850 @ $0.5 vs 2800 OI; Ref=$16.35,2017-10-24 14:15:00-04:00,PTCT,positive
1040250.0,REMINDER: PTC Therapeutics Has PDUFA Date For Ataluren Today,2017-10-24 08:56:00-04:00,PTCT,neutral
1040251.0,"PTC Therapeutics Shares Fall ~$0.30 From Recent Highs As Traders Circulate Article From Regional Paper Highlighting 1 Man's Struggle With MS; Includes 'According to PTC, the FDA will notify the company by Tuesday whether or not ataluren has been approved'",2017-10-23 12:53:00-04:00,PTCT,positive
1040252.0,"PTC Therapeutics Shares Spike ~$0.10, Now Paring Gains And Largely Unaffected; Traders Circulating New Haven Register Article 'Man awaits FDA decision on drug that treats muscular dystrophy'",2017-10-23 12:51:00-04:00,PTCT,positive
1040253.0,"PTC Therapeutics Reports Conclusion Of Dose-Finding Part OF SUNFISH Study, Triggers $20M Payment From Roche To Co.",2017-10-12 08:07:00-04:00,PTCT,neutral
1040254.0,Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics?,2017-10-09 13:52:00-04:00,PTCT,neutral
1040255.0,18 Biggest Mid-Day Losers For Monday,2017-10-09 12:55:00-04:00,PTCT,negative
1040256.0,Mid-Morning Market Update: Markets Mostly Flat; Axalta Lowers 2017 Forecast,2017-10-09 10:09:00-04:00,PTCT,negative
1040257.0,"Benzinga's Top Upgrades, Downgrades For October 9, 2017",2017-10-09 09:15:00-04:00,PTCT,positive
1040258.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-09 08:08:00-04:00,PTCT,neutral
1040259.0,JP Morgan Downgrades PTC Therapeutics to Underweight,2017-10-09 07:16:00-04:00,PTCT,positive
1040260.0,PTC Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy,2017-10-03 10:14:00-04:00,PTCT,positive
1040261.0,Watch These 7 Huge Call Purchases In Monday Trade,2017-10-02 04:12:00-04:00,PTCT,positive
1040262.0,Benzinga's Option Alert Recap From September 29,2017-09-29 16:08:00-04:00,PTCT,positive
1040263.0,U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely',2017-09-29 14:15:00-04:00,PTCT,positive
1040264.0,18 Biggest Mid-Day Gainers For Friday,2017-09-29 12:10:00-04:00,PTCT,neutral
1040265.0,PTC Therapeutics Option Alert: Dec 15 $30 Calls Sweep (4) at the Ask: 800 @ $0.5 vs 23 OI; Ref=$19.88,2017-09-29 10:23:00-04:00,PTCT,positive
1040266.0,16 Stocks Moving In Friday's Pre-Market Session,2017-09-29 09:02:00-04:00,PTCT,neutral
1040267.0,PTC Shares Rebounding From After-Hour Lows; Stock Down ~1.2%,2017-09-28 17:53:00-04:00,PTCT,positive
1040268.0,"PTC Therapeutics Shares Resume, Down ~12.4%",2017-09-28 17:50:00-04:00,PTCT,positive
1040269.0,PTC Shares To Resume Trade At 5:50 p.m. EDT,2017-09-28 17:47:00-04:00,PTCT,positive
1040270.0,"Recent 8-K From PTC Showed 10 Members Of AdCom Panel Voted Translarna Could Be Effective, But Data Are Inconclusive, And More Week Would Be Needed...To Establish [Effectiveness]; 1 Member Voted 'Data Are Sufficient To Conclude [Translarna] Is Effective'",2017-09-28 17:47:00-04:00,PTCT,positive
1040271.0,"FDA AdCom Panel Says PTC's DMD Treatment 'May Work' But Data Is Inconclusive, More Work Needed To Be Done",2017-09-28 15:36:00-04:00,PTCT,neutral
1040272.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,PTCT,neutral
1040273.0,UPDATE: PTC Therapeutics Shares Halted Ahead Of FDA AdCom Panel Meeting For Translarna,2017-09-28 07:27:00-04:00,PTCT,positive
1040274.0,PTC Therapeutics Shares Halted News Pending,2017-09-28 06:58:00-04:00,PTCT,positive
1040275.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-26 13:04:00-04:00,PTCT,negative
1040276.0,Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna,2017-09-26 12:32:00-04:00,PTCT,positive
1040277.0,"PTC Therapeutics Shares At New Session Low, Down 24%",2017-09-26 10:10:00-04:00,PTCT,neutral
1040278.0,STAT News Adam Feuerstein Publishes 'FDA rips into PTC's Duchenne muscular dystrophy drug as advisory panel looms',2017-09-26 09:31:00-04:00,PTCT,negative
1040279.0,"Adam Feuerstein Tweets: The FDA's briefing document on $PTCT Translarna is wonderfully transparent, offers great behind-scenes look at regulatory process.",2017-09-26 09:25:00-04:00,PTCT,positive
1040280.0,UPDATE: PTC Therapeutics AdCom Panel Briefing Doc Shows 'more work would be needed to establish whether ataluren is effective',2017-09-26 09:21:00-04:00,PTCT,positive
1040281.0,"PTC Therapeutics Shares Down 15% In Pre-Market Action, Up ~$1.60 From $15 Low; AdCom Panel Briefing Docs Made Available Today; Panel Meeting Is Thursday, Sept. 28",2017-09-26 09:13:00-04:00,PTCT,neutral
1040282.0,"Seeing Profit Taking In PTC Therapeutics Shares Fri., Down 6% As $20 Support Level Fails To Hold; Stock Has Rallied 120% Since End Of May",2017-09-22 13:48:00-04:00,PTCT,positive
1040283.0,William Blair Initiates Coverage On PTC Therapeutics with Market Perform Rating,2017-08-23 09:22:00-04:00,PTCT,neutral
1040284.0,"PTC Therapeutics Reports Q2 Loss/Share $(0.44) vs. $(1.48) Est., Sales $47.96M vs. $28.78M Est.",2017-08-08 17:01:00-04:00,PTCT,neutral
1040285.0,Adam Feuerstein Tweets: Is the FDA telegraphing a rejection for $PTCT DMD drug? —> statnews.com/2017/08/01/ptc…,2017-08-01 13:18:00-04:00,PTCT,negative
1040286.0,"Lightning Round: Jim Cramer Advises His Viewers On Hertz, Macy's And More",2017-07-26 07:13:00-04:00,PTCT,neutral
1040287.0,Benzinga's Option Alert Recap From July 19,2017-07-19 16:18:00-04:00,PTCT,positive
1040288.0,PTC Therapeutics Option Alert: Aug 18 $20 Calls Above Ask!: 500 @ $1.611 vs 46 OI; Ref=$19.57,2017-07-19 12:12:00-04:00,PTCT,positive
1040289.0,18 Biggest Mid-Day Gainers For Tuesday,2017-06-06 12:30:00-04:00,PTCT,neutral
1040290.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-06 08:12:00-04:00,PTCT,neutral
1040291.0,"PTC Therapeutics Reports FDA Panel Meeting for Ataluren for Treatment of Nonsense Mutation Dystrophinopathy on Oct. 24, 2017",2017-06-06 08:02:00-04:00,PTCT,negative
1040292.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-06-06 05:00:00-04:00,PTCT,positive
1040293.0,Option Alert: PTC Therapeutics  Dec17 18.0 Calls: 2500 @  ASK  $2.00: 2500 traded vs 277 OI:  Earnings 8/3 Before Open (est)  $13.12 Ref,2017-06-05 11:18:00-04:00,PTCT,positive
1040294.0,PTC Therapeutics Names Marcio Souza COO,2017-06-05 08:01:00-04:00,PTCT,neutral
1040295.0,PTC Therapeutics Moves On Old Report,2017-06-01 12:13:00-04:00,PTCT,neutral
1040296.0,PTC Therpapeutics Spokesperson Tells Benzinga 'This is Very Old News...Phase 3 was Completed Almost Two Years Ago',2017-06-01 11:39:00-04:00,PTCT,neutral
1040297.0,PTC Study Of Ataluren Has Been Terminated,2017-06-01 09:52:00-04:00,PTCT,neutral
1040298.0,"PTC Therapeutics Reports Q1 Sales $26.54M vs $28.6M Est., EPS $(0.85) vs $(1.03) Est.",2017-05-08 07:45:00-04:00,PTCT,neutral
1040299.0,PTC Therapeutics CFO Shane Kovacs To Leave Company,2017-04-10 16:03:00-04:00,PTCT,negative
1040300.0,PTC Therapeutics Pops to High of $9.11 on Volume,2017-03-30 14:37:00-04:00,PTCT,neutral
1040301.0,Adam Feuerstein Tweets: $PTCT withdrew the EMA application for Translarna in cystic fibrosis. ema.europa.eu/ema/pages/incl…,2017-03-24 08:09:00-04:00,PTCT,neutral
1040302.0,PTC Therapeutics Shares Dip ~$0.17 Over Last Min as Traders Circulating Press Release from Oversight & Gov't Reform 'Sanders and Cummings Request Pricing Info From PTC Therapeutics for Critical Drug',2017-03-22 15:15:00-04:00,PTCT,neutral
1040303.0,"Wall Street's M&A Chatter From March 17: Wynn, Innocoll, PTC Therapeutics",2017-03-17 06:50:00-04:00,PTCT,neutral
1040304.0,"Adam Feuerstein Tweets: $PTCT plans to ""reexamine"" Emflaza price.",2017-03-16 08:42:00-04:00,PTCT,neutral
1040305.0,PTCT To Acquire Emflaza From Marathon For $140M Compromising Of Cash And Stock,2017-03-16 07:42:00-04:00,PTCT,neutral
1040306.0,PTC Sees FY17 Ex-US Translarna Net Sales $105M-$125M,2017-03-16 07:36:00-04:00,PTCT,neutral
1040307.0,"PTC Therapeutics Reports Q4 Loss $26.8M vs $50.9M in Same Qtr. Last Year, Sales $25.2M",2017-03-16 07:36:00-04:00,PTCT,negative
1040308.0,"PTC Therapeutics to Buy Emflaza for Treatment of DMD in US from Marathon Pharma for Upfront Consideration of $140M, Single Sales-Based Milestone of $50M",2017-03-16 07:20:00-04:00,PTCT,neutral
1040309.0,"Earnings Scheduled For March 16, 2017",2017-03-16 04:05:00-04:00,PTCT,neutral
1040310.0,"Earnings Scheduled For March 14, 2017",2017-03-14 04:44:00-04:00,PTCT,neutral
1040311.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,PTCT,neutral
1040312.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,PTCT,neutral
1040313.0,PTC Therapeutics Reports FDA Acknowledgment of NDA Filing for Translarna,2017-03-06 08:07:00-05:00,PTCT,neutral
1040314.0,8 Biggest Price Target Changes For Friday,2017-03-03 09:59:00-05:00,PTCT,neutral
1040315.0,"Benzinga's Top Upgrades, Downgrades For March 3, 2017",2017-03-03 09:28:00-05:00,PTCT,positive
1040316.0,"Barclays Downgrades PTC Therapeutics to Equal-Weight, Lowers Price Target to $13.00",2017-03-03 08:13:00-05:00,PTCT,negative
1040317.0,Mid-Afternoon Market Update: Crude Oil Down 2%; Ameresco Shares Spike Higher,2017-03-02 14:30:00-05:00,PTCT,negative
1040318.0,20 Biggest Mid-Day Losers For Thursday,2017-03-02 13:05:00-05:00,PTCT,negative
1040319.0,"PTC Therapeutics Sharply Lower After ACT CF Trial Misses Primary, Secondary Endpoints",2017-03-02 11:20:00-05:00,PTCT,negative
1040320.0,Mid-Morning Market Update: Markets Edge Lower; Abercrombie & Fitch Earnings Miss Views,2017-03-02 10:00:00-05:00,PTCT,negative
1040321.0,"PTC Therapeutics Shares Resume, Now Down 27%",2017-03-02 08:32:00-05:00,PTCT,positive
1040322.0,PTC Therapeutics to Resume at 8:30 AM ET,2017-03-02 08:09:00-05:00,PTCT,neutral
1040323.0,PTC Therapeutics Shares to Resume Trade at 8:30 a.m. EST,2017-03-02 08:09:00-05:00,PTCT,positive
1040324.0,UPDATE: PTC Plans To Discontinue Curent Clinical Development of ataluren In CF Close Ongoing Extension Studies And Withdraw Marketing Application Authorization In Europe,2017-03-02 08:01:00-05:00,PTCT,neutral
1040325.0,PTC Therapeutics ACT CF Trial Missed Primary And Secondary Endpoints,2017-03-02 08:00:00-05:00,PTCT,negative
1040326.0,PTC Therapeutics Halted News Pending,2017-03-02 07:55:00-05:00,PTCT,neutral
1040327.0,Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100,2017-02-16 10:45:00-05:00,PTCT,positive
1040328.0,Credit Suisse In Note Says They Think PTC Therapeutics Could Trade Up To $80-$100/Share Believes It Has A Compelling Risk/Reward Setup  Coming Into CF Data,2017-02-16 09:43:00-05:00,PTCT,positive
1040329.0,Watch These 8 Huge Call Purchases In Wednesday Trade,2017-01-18 04:04:00-05:00,PTCT,positive
1040330.0,Option Alert: PTC Therapeutics Mar 18.0 Calls Sweep: 853 @  ASK  $2.091: 883 traded vs 99 OI:  Earnings 2/28 After Close (est)  $14.70 Ref,2017-01-17 15:43:00-05:00,PTCT,positive
1040331.0,"PTC Therapeutics Sees FY16 Cash Of $230M, FY17 Cash Of ~$160M",2017-01-09 08:12:00-05:00,PTCT,neutral
1040332.0,PTC Therapeutics Granted Orphan Drug Designation for RG7916 for Treatment of Spinal Muscular Atrophy,2017-01-06 08:01:00-05:00,PTCT,positive
1040333.0,PTC Therapeutics Reports Initiation of FIREFISH Study in Infant SMA Patients,2017-01-05 08:01:00-05:00,PTCT,neutral
1040334.0,PTC Therapeutics Sells off to Low of $11.99 on Volume,2016-12-15 14:20:00-05:00,PTCT,negative
1040335.0,18 Biggest Mid-Day Gainers For Monday,2016-11-14 12:30:00-05:00,PTCT,neutral
1040336.0,Credit Suisse Upgrade Keeps The Rally Going In PTC Therapeutics,2016-11-14 10:59:00-05:00,PTCT,positive
1040337.0,7 Biggest Price Target Changes For Monday,2016-11-14 09:35:00-05:00,PTCT,neutral
1040338.0,The Market In 5 Minutes: A Couple Of Pharma Stocks Move 70% In Opposite Directions,2016-11-14 09:04:00-05:00,PTCT,neutral
1040339.0,Benzinga's Top Upgrades,2016-11-14 08:46:00-05:00,PTCT,positive
1040340.0,18 Stocks Moving In Monday's Pre-Market Session,2016-11-14 08:23:00-05:00,PTCT,neutral
1040341.0,"PTC Therapeutics+ 14.87% Premarket @$12.98; Credit Suisse Upgrades to Outperform, Raises PT to $25.00",2016-11-14 07:20:00-05:00,PTCT,positive
1040342.0,"Credit Suisse Upgrades PTC Therapeutics, Inc. - Common Stock to Outperform, Raises to $25.00",2016-11-14 05:56:00-05:00,PTCT,positive
1040343.0,Mid-Afternoon Market Update: Gold Futures Down 3.5%; PTC Therapeutics Shares Spike Higher,2016-11-11 14:24:00-05:00,PTCT,positive
1040344.0,12 Biggest Mid-Day Gainers For Friday,2016-11-11 12:28:00-05:00,PTCT,neutral
1040345.0,Mid-Day Market Update: Crude Oil Down Over 3%; NVIDIA Shares Jump On Earnings Beat,2016-11-11 12:10:00-05:00,PTCT,negative
1040346.0,A Timeline Of PTC Therapeutics' Translarna Journey,2016-11-11 11:58:00-05:00,PTCT,neutral
1040347.0,Technical Alert - PTC Therapeutics Inc. Sharply Higher EMA Decision,2016-11-11 11:25:00-05:00,PTCT,positive
1040348.0,Benzinga's Volume Movers,2016-11-11 10:33:00-05:00,PTCT,neutral
1040349.0,Mid-Morning Market Update: Markets Mostly Lower; J C Penney Q3 Sales Miss Estimates,2016-11-11 10:04:00-05:00,PTCT,negative
1040350.0,"Citigroup Upgrades PTC Therapeutics, Inc. - Common Stock to Buy, Raises to $15.00",2016-11-11 09:35:00-05:00,PTCT,neutral
1040351.0,Sarepta +5.7% Premarket Following EMA Renewal of Marketing Authorization for PTC's Translarna,2016-11-11 08:55:00-05:00,PTCT,neutral
1040352.0,PTC Therapeutics Surges 88% On European Marketing Authorization,2016-11-11 08:46:00-05:00,PTCT,neutral
1040353.0,18 Stocks Moving In Friday's Pre-Market Session,2016-11-11 08:21:00-05:00,PTCT,neutral
1040354.0,"Adam Feuerstein @adamfeuerstein Tweet: EMA's flexibility w/ $PTCT Ataluren has to be positive for $SRPT Exondys, right? Logically consistent?",2016-11-11 07:29:00-05:00,PTCT,positive
1040355.0,PTC Therapeutics Spikes to High of $10.99 Premarket; CHMP Recommended Renewal of Translarna's Marketing Authorization for Nonsense Mutation DMD,2016-11-11 07:23:00-05:00,PTCT,negative
1040356.0,"PTC Therapeutics, Inc. Reports CHMP Recommends Renewal of Translarna's Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment",2016-11-11 07:16:00-05:00,PTCT,positive
1040357.0,20 Biggest Mid-Day Losers For Thursday,2016-11-03 13:00:00-04:00,PTCT,negative
1040358.0,"PTC Therapeutics Reports Q3 EPS $(1.03) vs. Est. $(1.22), Rev. $22.98M vs. Est. $19.7M",2016-11-02 17:56:00-04:00,PTCT,neutral
1040359.0,16 Stocks Moving In Friday's Pre-Market Session,2016-10-21 08:43:00-04:00,PTCT,neutral
1040360.0,PTC Therapeutics Says 'Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients',2016-10-20 16:32:00-04:00,PTCT,neutral
1040361.0,PTC Therapeutics Reports Spinal Muscular Atrophy Program via RG7916 Advances into Phase 2 Studies in SMA Patients,2016-10-20 16:32:00-04:00,PTCT,neutral
1040362.0,Technical Alert: PTC Therapeutics Continues Lower,2016-10-18 13:10:00-04:00,PTCT,neutral
1040363.0,Mid-Afternoon Market Update: Dow Falls Over 50 Points; RLJ Entertainment Shares Spike Higher,2016-10-17 14:53:00-04:00,PTCT,positive
1040364.0,12 Biggest Mid-Day Losers For Monday,2016-10-17 13:27:00-04:00,PTCT,negative
1040365.0,Mid-Day Market Update: Hasbro Gains On Earnings Beat; PTC Therapeutics Shares Slide,2016-10-17 12:14:00-04:00,PTCT,positive
1040366.0,PTC Therapeutics Down 30% Off FDA Denial Letter,2016-10-17 11:01:00-04:00,PTCT,neutral
1040367.0,Mid-Morning Market Update: Markets Edge Lower; Bank of America Profit Tops Views,2016-10-17 10:14:00-04:00,PTCT,positive
1040368.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-17 08:46:00-04:00,PTCT,neutral
1040369.0,UPDATE: PTC Therapeutics Says Intends to Escalate Appeal to Next Supervisory Level of FDA,2016-10-17 08:09:00-04:00,PTCT,neutral
1040370.0,"PTC Therapeutics Reports Regulatory Update on Translarna for Nonsense Mutation DMD: FDA's ODE-I Denied Co. First Appeal of Refuse of File Letter Issued by DNP on Feb. 22, '16",2016-10-17 08:09:00-04:00,PTCT,negative
1040371.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-06 08:43:00-04:00,PTCT,neutral
1040372.0,Option Alert: PTCT Oct16 14.0 Calls Sweep: 500 @  ASK  $1.10: 515 traded vs 863 OI:  Earnings 11/14  $13.53 Ref,2016-10-04 11:46:00-04:00,PTCT,positive
1040373.0,15 Biggest Mid-Day Gainers For Friday,2016-09-30 12:40:00-04:00,PTCT,neutral
1040374.0,Camber Capital Management Reports 5.84% Passive Stake in PTC Therapeutics in 13G,2016-09-29 10:46:00-04:00,PTCT,positive
1040375.0,3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering,2016-09-22 15:22:00-04:00,PTCT,positive
1040376.0,Jefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics,2016-09-20 10:44:00-04:00,PTCT,positive
1040377.0,Technical Alert: PTC Therapeutics Moves In Sympathy With Sarepta Therapeutics,2016-09-19 15:28:00-04:00,PTCT,positive
1040378.0,15 Biggest Mid-Day Gainers For Monday,2016-09-19 12:36:00-04:00,PTCT,neutral
1040379.0,PTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval,2016-09-19 12:32:00-04:00,PTCT,positive
1040380.0,Sarepta Shares Now Up 95% to ~$55; PTC Therapeutics Shares Up 27% as Traders Viewing Accelerated Approval Filing by FDA on Sarepta's Eteplirsen as Sympathy Event for PTCT,2016-09-19 11:41:00-04:00,PTCT,positive
1040381.0,PTC Therapeutics Spikes to High of $9.29 on Volume,2016-09-14 10:51:00-04:00,PTCT,neutral
1040382.0,"The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A",2016-09-14 09:17:00-04:00,PTCT,positive
1040383.0,Can You Guess This Chart?,2016-09-14 07:29:00-04:00,PTCT,neutral
1040384.0,PTC Therapeutics Spikes to High of $8.47 on Volume; Traders Circulating Report of NICE Recommendation,2016-08-25 11:05:00-04:00,PTCT,positive
1040385.0,Mid-Afternoon Market Update: Dow Up 160 Points; Lantheus Shares Surge On Earnings Beat,2016-08-05 14:49:00-04:00,PTCT,positive
1040386.0,25 Biggest Mid-Day Gainers For Friday,2016-08-05 12:43:00-04:00,PTCT,neutral
1040387.0,"PTC Therapeutics Reports Q2 $(1.14) vs. Est. $(1.27), Rev. $15.633M vs. Est. $14.6M",2016-08-04 17:50:00-04:00,PTCT,neutral
1040388.0,Benzinga's Top Initiations,2016-08-01 09:30:00-04:00,PTCT,positive
1040389.0,15 Biggest Mid-Day Losers For Tuesday,2016-07-26 12:53:00-04:00,PTCT,negative
1040390.0,8 Biggest Price Target Changes For Tuesday,2016-07-26 10:02:00-04:00,PTCT,neutral
1040391.0,"Need For New Drug Trial Increases Long-Term Risk For PTC Therapeutics, Says Wedbush",2016-07-26 09:04:00-04:00,PTCT,negative
1040392.0,"Credit Suisse Downgrades PTC Therapeutics to Neutral, Lowers PT to $6.00",2016-07-26 04:27:00-04:00,PTCT,positive
1040393.0,UPDATE: PTC Therapeutics Initiated Pediatric Clinical Study of Translarna for Treatment of nnDMD in Patients 2-5 in Age,2016-07-25 10:48:00-04:00,PTCT,neutral
1040394.0,UPDATE: PTC Therapeutics Says Renewal Assessment Prodedure with CHMP 'cannot be completed by mid-year 2016',2016-07-25 10:47:00-04:00,PTCT,neutral
1040395.0,PTC Therapeutics Offers Regulatory Update on Translarna,2016-07-25 10:46:00-04:00,PTCT,neutral
1040396.0,NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy,2016-07-20 09:51:00-04:00,PTCT,positive
1040397.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-07-07 08:27:00-04:00,PTCT,neutral
1040398.0,Adam Feuerstein @adamfeuerstein Tweet: No decision on $PTCT Translarna out of EMA CHMP today.,2016-06-24 07:31:00-04:00,PTCT,negative
1040399.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-05-25 08:21:00-04:00,PTCT,neutral
1040400.0,"PTC THerapeutics Reports Q1 EPS $(1.22) Vs Est $(1.26), Sales $18.878M Vs Est $13.74M",2016-05-05 16:56:00-04:00,PTCT,neutral
1040401.0,PTC Therapeutics Says Canceled DB Conference Appearance on March 29 Due to Investor Call on May 5,2016-04-27 11:36:00-04:00,PTCT,neutral
1040402.0,Hearing PTC Therapeutics Cancelled Out of DB Conference,2016-04-27 10:34:00-04:00,PTCT,negative
1040403.0,PTC Therapeutics Names Dr. Tuyen Ong as Chief Medical Officer,2016-04-26 16:23:00-04:00,PTCT,neutral
1040404.0,Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares,2016-04-18 13:30:00-04:00,PTCT,positive
1040405.0,"PTC Therapeutics Investors Taking Profits Monday Following ~42% Rally on Friday, Stock Down ~5%; Downside Comes Amid Earlier Positive Comments from Oppenheimer",2016-04-18 10:19:00-04:00,PTCT,positive
1040406.0,10 Stocks Moving In Monday's Pre-Market Session,2016-04-18 08:22:00-04:00,PTCT,neutral
1040407.0,Mid-Afternoon Market Update: Infosys Rises Following Q4 Results; Ixia Shares Slide,2016-04-15 15:29:00-04:00,PTCT,positive
1040408.0,PTC Therapeutics Spikes 40% After Translarna Update In England,2016-04-15 13:45:00-04:00,PTCT,neutral
1040409.0,"Shares of PTC Therapeutics Resume Trade, Now Up 19.9%",2016-04-15 11:23:00-04:00,PTCT,positive
1040410.0,PTC Therapeutics Shares to Resume Trade 11:22:30,2016-04-15 11:21:00-04:00,PTCT,positive
1040411.0,"PTC Shares Halted on Circuit Breaker, Now Up 14%",2016-04-15 11:18:00-04:00,PTCT,positive
1040412.0,PTC Therapeutics Announces NICE Recommends Translarna For Patient Treatment Of Nonsense Mutation DMD In England,2016-04-15 11:17:00-04:00,PTCT,positive
1040413.0,Why These 5 Stocks Are Moving After Hours,2016-03-23 16:55:00-04:00,PTCT,neutral
1040414.0,"PTC Therapeutics Reports Workforce Reduction By 18%, Will Incur $2.5M Charge",2016-03-23 16:03:00-04:00,PTCT,neutral
1040415.0,PTC Therapeutics Offers Update on Health Canada Review of Translarna for Treatment of DMD,2016-03-14 08:07:00-04:00,PTCT,neutral
1040416.0,PTC Therapeutics To Withdraw Current NDS From Health Caanada To Resubmit With ACT DMD Results; Expects Review In 1H 2016,2016-03-14 08:05:00-04:00,PTCT,neutral
1040417.0,PTC Therapeutics Reports Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology,2016-03-14 08:04:00-04:00,PTCT,neutral
1040418.0,11 Stocks Moving In Wednesday's Pre-Market Session,2016-03-02 08:15:00-05:00,PTCT,neutral
1040419.0,PTC Therapeutics Announces Inducement Grants for Non-Statutory Stock Options to Buy 29.5K Shares of Common Stock to 12 New Employees,2016-03-02 08:10:00-05:00,PTCT,positive
1040420.0,Mid-Afternoon Market Update: American Public Education Rises Following Q4 Results; PTC Therapeutics Shares Fall,2016-03-01 14:26:00-05:00,PTCT,positive
1040421.0,Wall Street Really Blew It On PTC Therapeutics,2016-03-01 13:37:00-05:00,PTCT,neutral
1040422.0,Stocks Hitting 52-Week Lows,2016-03-01 10:21:00-05:00,PTCT,negative
1040423.0,PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna,2016-03-01 09:21:00-05:00,PTCT,negative
1040424.0,"Jefferies Maintains Hold on PTC Therapeutics, Lowers PT to $8.00",2016-03-01 08:25:00-05:00,PTCT,negative
1040425.0,Wedbush Downgrades PTC Therapeutics to Neutral,2016-03-01 07:26:00-05:00,PTCT,neutral
1040426.0,Cowen & Company Downgrades PTC Therapeutics to Market Perform,2016-03-01 06:55:00-05:00,PTCT,neutral
1040427.0,"Credit Suisse Maintains Outperform on PTC Therapeutics, Lowers PT to $12.00",2016-03-01 05:59:00-05:00,PTCT,positive
1040428.0,"Barclays Maintains Overweight on PTC Therapeutics, Lowers PT to $40.00",2016-03-01 04:17:00-05:00,PTCT,negative
1040429.0,7 Stocks Moving In Today's After-Hours Session,2016-02-29 18:01:00-05:00,PTCT,neutral
1040430.0,"PTC Therapeutics Says RTF Letter Received from FDA Related to Translarna for nmDMD, Translarna EU Regulatory Submissions for DMD, CF Under Review by CHMP",2016-02-29 16:04:00-05:00,PTCT,neutral
1040431.0,PTC Therapeutics Sees FY16 Sales Ex-US Translarna nmDMD $65M-$85M vs $94.9M Est.,2016-02-29 16:03:00-05:00,PTCT,neutral
1040432.0,"PTC Therapeutics Reports Q4 EPS $(1.50) vs $(1.25) Est., Sales $12.734M vs $13.2M Est.",2016-02-29 16:02:00-05:00,PTCT,neutral
1040433.0,What You May Be Missing About PTC Therapeutics In Germany,2016-02-29 09:05:00-05:00,PTCT,negative
1040434.0,Bank of America Downgrades PTC Therapeutics to Neutral,2016-02-29 08:58:00-05:00,PTCT,neutral
1040435.0,"Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review",2016-02-29 08:08:00-05:00,PTCT,neutral
1040436.0,"Earnings Scheduled For February 29, 2016",2016-02-29 04:04:00-05:00,PTCT,neutral
1040437.0,UPDATE: Cowen & Co Reviewing Recommendation On PTCT Citing Need For Clarity On Translarna's US/EU Value,2016-02-27 10:06:00-05:00,PTCT,positive
1040438.0,"Cowen & Co Places Outperform Rating 'Under Review' For PTC Therapeutics, Removes $120 PT",2016-02-27 10:01:00-05:00,PTCT,neutral
1040439.0,PTC Therapeutics Confirms Early Reports,2016-02-26 16:01:00-05:00,PTCT,neutral
1040440.0,Adam Feuerstein @adamfeuerstein Tweet: BREAKING $PTCT: German reimbursement arbitration panel cuts price of DMD drug ataluren by 65%. (Decision Feb. 25) pic.twitter.com/dPyMdza7U5,2016-02-26 15:34:00-05:00,PTCT,negative
1040441.0,"Benzinga's M&A Chatter for Thursday February 25, 2016",2016-02-25 20:58:00-05:00,PTCT,neutral
1040442.0,PTC Therapeutics Mounts Tepid Comeback,2016-02-25 16:27:00-05:00,PTCT,neutral
1040443.0,Sanofi Spokesperson on Word of PTC Therapeutics Interest Tells Benzinga Co. 'Does Not Comment on Market Rumors',2016-02-25 13:35:00-05:00,PTCT,positive
1040444.0,EXCLUSIVE: Sanofi In Talks To Buy PTC Therapeutics,2016-02-25 13:32:00-05:00,PTCT,positive
1040445.0,Street Insider Reports Sanofi Could Bid for PTC Therapeutics,2016-02-25 13:22:00-05:00,PTCT,neutral
1040446.0,PTC Therapeutics Spikes to High of $12.26 on Volume,2016-02-25 13:19:00-05:00,PTCT,neutral
1040447.0,Shares of PTC Therapeutics Spike Higher,2016-02-25 13:19:00-05:00,PTCT,positive
1040448.0,Oppenheimer Sees 'Significant Upside Potential' In PTC Therapeutics,2016-02-25 10:47:00-05:00,PTCT,positive
1040449.0,"Oppenheimer Reiterates Outperform on PTC Therapeutics, Lowers PT to $111.00",2016-02-25 07:35:00-05:00,PTCT,negative
1040450.0,Benzinga's Top Upgrades,2016-02-24 09:21:00-05:00,PTCT,positive
1040451.0,Benzinga's Top Downgrades,2016-02-24 09:15:00-05:00,PTCT,positive
1040452.0,Jefferies Upgrades PTC Therapeutics To Hold; Sees FDA Approvalability Priced In And Is Uncertain On EU Decision,2016-02-24 08:44:00-05:00,PTCT,negative
1040453.0,Citi Downgrades PTC Therapeutics Following Major Setback,2016-02-24 08:06:00-05:00,PTCT,neutral
1040454.0,Citigroup Downgrades PTC Therapeutics to Neutral,2016-02-24 06:51:00-05:00,PTCT,neutral
1040455.0,"RBC Capital Downgrades PTC Therapeutics to Sector Perform, Lowers PT to $11.00",2016-02-24 06:14:00-05:00,PTCT,negative
1040456.0,Jefferies Upgrades PTC Therapeutics to Hold,2016-02-24 06:14:00-05:00,PTCT,neutral
1040457.0,Mid-Afternoon Market Update: Fitbit Drops On Weak Forecast; MRC Global Shares Surge,2016-02-23 14:53:00-05:00,PTCT,negative
1040458.0,PTC Therapeutics Down 56% After Receipt Of Refuse To File Letter For Translama,2016-02-23 13:59:00-05:00,PTCT,negative
1040459.0,Mid-Day Market Update: Crude Oil Down 4.5%; Newport Shares Spike Higher,2016-02-23 12:20:00-05:00,PTCT,negative
1040460.0,"JP Morgan Downgrades PTC Therapeutics to Neutral, Lowers PT to $22.00, Removed From Focus List",2016-02-23 11:27:00-05:00,PTCT,positive
1040461.0,Mid-Morning Market Update: Markets Open Lower; Home Depot Beats Q4 Estimates,2016-02-23 10:14:00-05:00,PTCT,negative
1040462.0,Stocks Hitting 52-Week Lows,2016-02-23 10:10:00-05:00,PTCT,negative
1040463.0,PTC Therapeutics Shares Fall 29% Premarket to $20 Following Announcement of Receipt of Refuse to File Letter from FDA for Translarna,2016-02-23 08:18:00-05:00,PTCT,neutral
1040464.0,"Shares Of PTC Therapeutics Fall From 28.26 To $20.05, Down 29% After Refusal To File Letter From FDA For Translarna",2016-02-23 08:17:00-05:00,PTCT,positive
1040465.0,"PTC Receives Refuse to File Letter from FDA for Translarna, Application Was Not Complete To Permit A Substantive Review",2016-02-23 08:15:00-05:00,PTCT,negative
1040466.0,Option Alert: PTCT Sep16 34.0 Calls Sweep: 576 @  ASK  $5.50: 576 traded vs 1 OI:  Earnings 2/26  $24.12 Ref,2016-02-11 13:49:00-05:00,PTCT,positive
1040467.0,The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug,2016-01-21 11:23:00-05:00,PTCT,neutral
1040468.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,PTCT,positive
1040469.0,"Credit Suisse Initiates Coverage on PTC Therapeutics at Outperform, Announces $36.00 PT",2016-01-19 16:19:00-05:00,PTCT,positive
1040470.0,Option Alert: PTCT Jan16 30.0 Puts Sweep: 517 @  ASK  $2.95: 548 traded vs 2870 OI: $32.18 Ref,2015-12-22 10:43:00-05:00,PTCT,positive
1040471.0,Oppenheimer Sees European Regulator Agenda Signaling Comming Decision On Adoption Of PTC Therapeutics Translama Drug,2015-12-16 10:25:00-05:00,PTCT,neutral
1040472.0,Morning Market Losers,2015-11-25 09:49:00-05:00,PTCT,negative
1040473.0,Benzinga's Top Downgrades,2015-11-25 09:32:00-05:00,PTCT,positive
1040474.0,Benzinga's Top #PreMarket Losers,2015-11-25 08:30:00-05:00,PTCT,negative
1040475.0,"Jefferies Downgrades PTC Therapeutics to Underperform, Lowers PT to $18.00",2015-11-25 07:29:00-05:00,PTCT,negative
1040476.0,PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis,2015-11-19 08:01:00-05:00,PTCT,neutral
1040477.0,"PTC Therapeutics Reports Q3 EPS ($1.27) Vs Est ($1.15), Sales $9.78M Vs Est $9.88M",2015-11-09 16:59:00-05:00,PTCT,neutral
1040478.0,Benzinga's Top Initiations,2015-10-23 08:20:00-04:00,PTCT,positive
1040479.0,"Jefferies Initiates Coverage on PTC Therapeutics at Hold, Announces $26.00 PT",2015-10-23 06:10:00-04:00,PTCT,neutral
1040480.0,Here's Why Biotechs Fell On Monday,2015-10-19 16:29:00-04:00,PTCT,neutral
1040481.0,Roth Capital On PTC Therapeutics: 'Staying On The Sidelines' Until Regulatory Clarity,2015-10-16 15:08:00-04:00,PTCT,positive
1040482.0,Option Alert: $PTCT Dec $20 Put Sweep; 3875 Contracts Above Ask @$1.79,2015-10-16 10:27:00-04:00,PTCT,positive
1040483.0,"Martin Shkreli @MartinShkreli Tweet: shorting $PTCT. sometimes these things take time to ""work"" and you have to ""pick your spots"".",2015-10-16 09:47:00-04:00,PTCT,neutral
1040484.0,Morning Market Gainers,2015-10-16 09:41:00-04:00,PTCT,neutral
1040485.0,"Oppenheimer Sees Translarna Approval 'Likely,' Believes PTC Is 'Catalyst Rich' Through 1H'16",2015-10-16 09:03:00-04:00,PTCT,positive
1040486.0,Benzinga's Top #PreMarket Gainers,2015-10-16 08:13:00-04:00,PTCT,positive
1040487.0,Barclays Thinks PTC Therapeutics Has 234% Upside,2015-10-16 07:16:00-04:00,PTCT,neutral
1040488.0,"Barclays Remains Overweight PTC Shares With Price Target Of $100/Share, Potential Upside Of 234%",2015-10-15 17:20:00-04:00,PTCT,negative
1040489.0,"Barclays Says, ""we are encouraged by the data and would be buyers of PTC shares. """,2015-10-15 17:19:00-04:00,PTCT,positive
1040490.0,"PTC Therapeutics Erasing Loses After Phase 3 Translarna Data Released, Touched Low of $19/Share After Hours; Now Trading At $30.57/Share",2015-10-15 17:18:00-04:00,PTCT,negative
1040491.0,"PTC Therapeutics Shares Resume, Trading Down ~21%",2015-10-15 16:35:00-04:00,PTCT,positive
1040492.0,"Martin Shkreli @MartinShkreli Tweet: This $PTCT trial was a ""redo"" of another failed trial and failed again. This drug has no efficacy whatsoever and an implausible/refuted MOA.",2015-10-15 16:34:00-04:00,PTCT,negative
1040493.0,UPDATE: PTC Phase 3 Trial Results Showed Translarna Was Not Statistically Significant in The Overall Intent-To-Treat Study Population,2015-10-15 16:23:00-04:00,PTCT,negative
1040494.0,UPDATE: PTC Therapeutics Says Primary Endpoint of Change from Baseline In 6-Minute Walk Test Demonstrated a 15 Meter Benefit And Wasn't Statistically Significant,2015-10-15 16:15:00-04:00,PTCT,positive
1040495.0,UPDATE: Primary Endpoint For PTC Phase 3 ACT DMD Clinical Trial  Strong Safety Profile Of Translarna Confirmed,2015-10-15 16:14:00-04:00,PTCT,positive
1040496.0,Shares of PTC Therapeutics to Resume Trade at 4:35 p.m. EDT,2015-10-15 16:10:00-04:00,PTCT,positive
1040497.0,Sarepta Spikes Higher After-Hours on PTC News,2015-10-15 16:08:00-04:00,PTCT,neutral
1040498.0,"UPDATE: PTC Says Data Shows Translarna's Ability to Slow Disease Progression, Pre-Specified Meta-Analysis of Combo Showed Benefit Across Primary, Key Secondary Efficacy Endponits",2015-10-15 16:07:00-04:00,PTCT,positive
1040499.0,PTC Therapeutics Reports Will Close Rolling NDA Submission for Translarna to FDA by End of '15,2015-10-15 16:06:00-04:00,PTCT,neutral
1040500.0,PTC Therapeutics Halted-News Pending,2015-10-15 16:01:00-04:00,PTCT,neutral
1040501.0,"PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts",2015-10-05 15:02:00-04:00,PTCT,neutral
1040502.0,PTC Therapeutics Phase 2 Data from Spinal Muscular Atrophy Program to be Presented at 20th International Annual Congress of WMS,2015-10-04 18:36:00-04:00,PTCT,neutral
1040503.0,PTC Therapeutics Submits European Application For Translarna for Cystic Fibrosis,2015-09-30 08:03:00-04:00,PTCT,neutral
1040504.0,Health Canada Initiates Review of PTC Therapeutics New Drug Submission for Translarna for Treatment of DMD,2015-09-18 08:04:00-04:00,PTCT,neutral
1040505.0,PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award,2015-09-04 08:01:00-04:00,PTCT,positive
1040506.0,"Citi Starts PTC Therapeutics At Buy, Sees One Of Year's Biggest Binary Events Coming",2015-08-25 09:32:00-04:00,PTCT,neutral
1040507.0,"Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics",2015-08-25 09:13:00-04:00,PTCT,positive
1040508.0,Treating Female Sexual Dysfunction (And How To Invest In It),2015-08-19 16:59:00-04:00,PTCT,negative
1040509.0,Option Alert: PTC Therapeutics Aug $80 Call Sweep; 1000 Contracts above Ask @$0.63; Now $58.71,2015-07-17 11:48:00-04:00,PTCT,positive
1040510.0,Mid-Day Market Update: Receptos Jumps After Merger News; Marten Transport Shares Slide,2015-07-15 13:03:00-04:00,PTCT,positive
1040511.0,Mid-Morning Market Update: Markets Mostly Higher; Bank Of America Tops Q2 Views,2015-07-15 10:56:00-04:00,PTCT,positive
1040512.0,Morning Market Gainers,2015-07-15 09:49:00-04:00,PTCT,neutral
1040513.0,Benzinga's Top Upgrades,2015-07-15 09:18:00-04:00,PTCT,positive
1040514.0,JP Morgan Upgrades PTC Therapeutics to Overweight,2015-07-15 06:47:00-04:00,PTCT,neutral
1040515.0,Seeing Cautious Note on PTC Therapeutics,2015-07-02 13:56:00-04:00,PTCT,negative
1040516.0,Watch These 10 After-Hours Movers Today,2015-06-23 06:59:00-04:00,PTCT,neutral
1040517.0,Hearing Deal Reporter Says Roche Looking at PTC Therapeutics,2015-06-02 10:35:00-04:00,PTCT,neutral
1040518.0,PTC Therapeutics: Quantifiable Added Benefit for First Approved Therapy for Nonsense Mutation Duchenne Muscular Dystrophy,2015-05-21 16:05:00-04:00,PTCT,positive
1040519.0,Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks,2015-05-06 17:41:00-04:00,PTCT,positive
1040520.0,"Credit Suisse Assumes PTC Therapeutics at Outperform, Announces $100.00 PT, Rated 'Top Idea'",2015-05-05 17:06:00-04:00,PTCT,positive
1040521.0,Benzinga's Top Downgrades,2015-05-05 09:29:00-04:00,PTCT,positive
1040522.0,Roth Capital Downgrades PTC Therapeutics To Neutral,2015-05-05 08:45:00-04:00,PTCT,neutral
1040523.0,"Roth Capital Downgrades PTC Therapeutics to Neutral, Lowers PT to $63.00",2015-05-05 06:24:00-04:00,PTCT,negative
1040524.0,PTC Therapeutics' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1,2015-04-28 08:06:00-04:00,PTCT,negative
1040525.0,"Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?",2015-04-27 10:59:00-04:00,PTCT,neutral
1040526.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,PTCT,negative
1040527.0,Phase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting,2015-04-20 08:01:00-04:00,PTCT,neutral
1040528.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,PTCT,neutral
1040529.0,Cowen Says PTC Therapeutics Is A Buy,2015-04-16 15:03:00-04:00,PTCT,neutral
1040530.0,Cowen & Company Upgrades PTC Therapeutics to Outperform,2015-04-16 09:12:00-04:00,PTCT,neutral
1040531.0,Is This Stock A Vertex Pharma Clone?,2015-04-10 20:54:00-04:00,PTCT,neutral
1040532.0,PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company -Adam F/Street.com,2015-03-24 10:42:00-04:00,PTCT,neutral
1040533.0,"Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst",2015-03-05 16:02:00-05:00,PTCT,positive
1040534.0,Barclays Expands Coverage To 7 New Biotech Stocks,2015-03-04 11:29:00-05:00,PTCT,positive
1040535.0,"Barclays Initiates Coverage on PTC Therapeutics at Overweight, Announces $100.00 PT",2015-03-04 06:43:00-05:00,PTCT,negative
1040536.0,JP Morgan Downgrades PTC Therapeutics to Neutral,2015-03-02 07:14:00-05:00,PTCT,positive
1040537.0,"PTC Therapeutics Reports Q4 EPS -$0.84 vs Est -$0.86, Sales $12.7M Vs Est $8.00M",2015-02-27 08:03:00-05:00,PTCT,neutral
1040538.0,"Earnings Scheduled For February 27, 2015",2015-02-27 05:14:00-05:00,PTCT,neutral
1040539.0,"Adam Feuerstein @adamfeuerstein Tweet: $PTCT for Sale? Only to a Foolish, Risk-Blind Buyer thestreet.com/story/13058217… via @TheStreet",2015-02-25 11:52:00-05:00,PTCT,negative
1040540.0,Adam Feuerstein @adamfeuerstein Tweet: The math used by Credit Suisse to raise its $PTCT price target to $100 from $66 assumes 100% probability of success for Ataluren DMD ph3.,2015-02-25 05:40:00-05:00,PTCT,positive
1040541.0,"UPDATE: Hearing Now that Vertex is Not Interested in PTC Therapeutics, They are Interested in a Cystic Fibrosis Play, PTC is Not a Major Cystic Fibrosis Play",2015-02-24 14:47:00-05:00,PTCT,positive
1040542.0,Hearing Unconfirmed Market Chatter of Vertex Interest in PTC Therapeutics,2015-02-24 14:42:00-05:00,PTCT,positive
1040543.0,Benzinga's Volume Movers,2015-02-24 11:05:00-05:00,PTCT,neutral
1040544.0,"Benzinga's M&A Chatter for Monday February 23, 2015",2015-02-23 17:31:00-05:00,PTCT,neutral
1040545.0,"Update: Biomarin, Shire Potential Buyers for PTC Therapeutics, According to Sources -Reuters",2015-02-23 12:30:00-05:00,PTCT,neutral
1040546.0,Adam Feuerstein @adamfeuerstein Tweet: $BMRN is interested in buying $PTCT? That's hard to believe.,2015-02-23 12:23:00-05:00,PTCT,positive
1040547.0,PTC Therapeutics Shares Rise 22% on Report of Potential Sale,2015-02-23 12:11:00-05:00,PTCT,positive
1040548.0,"PTC Therapeutics Exploring Sale, According to Sources -Reuters",2015-02-23 12:03:00-05:00,PTCT,neutral
1040549.0,Deutsche Bank Loves These Small-Cap Biotech Stocks,2015-01-22 11:09:00-05:00,PTCT,positive
1040550.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,PTCT,neutral
1040551.0,Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015,2015-01-11 12:59:00-05:00,PTCT,positive
1040552.0,PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy,2014-12-23 08:02:00-05:00,PTCT,positive
1040553.0,PTC Therapeutics' Translarna Granted Orphan Drug Designation In U.S. and Europe,2014-12-19 08:08:00-05:00,PTCT,positive
1040554.0,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635,2014-12-17 16:31:00-05:00,PTCT,positive
1040555.0,Shares of PTC Therapeutics Up Nearly 10% Over Last Hour as Hearing Traders Discussing DealReporter Alert Suggesting Shire or Sanofi Could Be Potential Suitors,2014-12-09 12:55:00-05:00,PTCT,positive
1040556.0,Martin Shkreli Tweet: @MartinShkreli shorting $PTCT,2014-12-04 14:28:00-05:00,PTCT,neutral
1040557.0,Shares of PTC Therapeutics Moving Lower on December 3 Article from UK's Chronicle Live Website on Translarna,2014-12-04 14:18:00-05:00,PTCT,neutral
1040558.0,PTC Therapeutics Announces Launch Of Translarna In Germany,2014-12-03 08:02:00-05:00,PTCT,neutral
1040559.0,Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA,2014-11-19 08:03:00-05:00,PTCT,neutral
1040560.0,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2014-11-17 16:31:00-05:00,PTCT,positive
1040561.0,Translarna Phase 2b Data Published In Muscle & Nerve ,2014-10-27 08:01:00-04:00,PTCT,neutral
1040562.0,UPDATE: Bank Of America Reiterates On PTC Therapeutics On Positive Outlook,2014-10-13 07:57:00-04:00,PTCT,positive
1040563.0,"Bank of America Maintains Buy on PTC Therapeutics, Lowers PT to $48.00",2014-10-13 05:54:00-04:00,PTCT,negative
1040564.0,PTC Therapeutics Prices 3M Share Offering @$36.25/Share,2014-10-09 19:11:00-04:00,PTCT,positive
1040565.0,PTC Therapeutics Prices Offering of 3M Shares at $36.25/Share,2014-10-09 18:36:00-04:00,PTCT,positive
1040566.0,PTC Therapeutics Reports 3M Share Offering,2014-10-08 16:25:00-04:00,PTCT,positive
1040567.0,PTC Therapeutics Presenting Now at Leering Rare Disease Roundtable,2014-10-01 08:26:00-04:00,PTCT,neutral
1040568.0,Benzinga's Volume Movers,2014-09-25 11:27:00-04:00,PTCT,neutral
1040569.0,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2014-09-24 16:31:00-04:00,PTCT,positive
1040570.0,"Midday Gainers From September 15 - RadioShack Corporation, Rewalk Robotics Ltd And More",2014-09-15 12:32:00-04:00,PTCT,neutral
1040571.0,Stocks Hitting 52-Week Highs,2014-09-15 10:04:00-04:00,PTCT,neutral
1040572.0,Benzinga's Top Initiations,2014-09-15 09:13:00-04:00,PTCT,positive
1040573.0,Deutsche Bank Initiates PTC Therapeutics At Buy,2014-09-15 07:39:00-04:00,PTCT,neutral
1040574.0,"Deutsche Bank Initiates Coverage on PTC Therapeutics at Buy, Announces $75.00 PT",2014-09-15 05:36:00-04:00,PTCT,neutral
1040575.0,PTC Therapeutics Reports Q2 EPS of $(0.86) vs $(0.75) Est; Revenue of $1.42M vs $1.71M Est,2014-08-07 07:38:00-04:00,PTCT,neutral
1040576.0,PTC Therapeutics Announce Conditional Approval in EU For Translarna,2014-08-04 12:42:00-04:00,PTCT,positive
1040577.0,PTC Therapeutics Reports Conditional Approval in EU for Translarna,2014-08-04 09:34:00-04:00,PTCT,positive
1040578.0,Biotech Enters Reporting Season With Large Caps Central To Sector Performance,2014-07-18 15:40:00-04:00,PTCT,neutral
1040579.0,"Roth Capital Initiates Coverage on PTC Therapeutics at Buy, Announces $34.00 PT",2014-07-07 08:40:00-04:00,PTCT,neutral
1040580.0,PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients With Nonsense Mutation Cystic Fibrosis (nmCF),2014-06-30 08:06:00-04:00,PTCT,negative
1040581.0,"Market Wrap For May 23: Markets Marginally Higher; S&P 500 Closes Above 1,900",2014-05-23 16:39:00-04:00,PTCT,neutral
1040582.0,#Premarket Prep Technical Update - PTC Therapeutics Trading Sharply Higher,2014-05-23 12:51:00-04:00,PTCT,neutral
1040583.0,Benzinga's Volume Movers ,2014-05-23 11:03:00-04:00,PTCT,neutral
1040584.0,"Morning Market Movers Friday, May 23, 2014",2014-05-23 10:44:00-04:00,PTCT,neutral
1040585.0,PTC Shares More Than Double Following CHMP's Positive Opinion On Translarna(TM),2014-05-23 08:56:00-04:00,PTCT,positive
1040586.0,Benzinga's Top #PreMarket Gainers ,2014-05-23 08:24:00-04:00,PTCT,positive
1040587.0,"Shares of PTC Rally Nearly 150% as Co. Gives Updates, Received Positive Opinion from CHMP on Translarna(TM)",2014-05-23 08:20:00-04:00,PTCT,positive
1040588.0,PTC Therapeutics Gives EMA Update,2014-05-23 07:30:00-04:00,PTCT,neutral
1040589.0,Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine,2014-05-16 08:03:00-04:00,PTCT,negative
1040590.0,PTC Therapeutics Reports Q4 EPS of $(0.75) vs $(0.57) Est; Revenue of $4.41M vs $6.15M Est,2014-03-06 16:05:00-05:00,PTCT,neutral
1040591.0,"PTC Therapeutics Closes Registered Offering, Reports Net Proceeds ~$118M",2014-02-19 13:01:00-05:00,PTCT,neutral
1040592.0,PTC Therapeutics Prices 4.489M Share Offering at $24.50/Share,2014-02-12 23:06:00-05:00,PTCT,positive
1040593.0,PTC Therapeutics Raises Secondary Offering from $75M to $100M,2014-02-12 13:55:00-05:00,PTCT,neutral
1040594.0,Benzinga's Top #PreMarket Losers,2014-01-24 08:26:00-05:00,PTCT,negative
1040595.0,"PTC Therapeutic, Roche Announce Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development ",2014-01-22 05:43:00-05:00,PTCT,neutral
1040596.0,The Five Best Performing Stocks of 2013 ,2013-12-26 07:54:00-05:00,PTCT,positive
1040597.0,PTC Therapeitics Reports Ataluren Clinical Data Demonstrate an Increase in Dystrophin Expression in nmDMD Patients ,2013-12-12 08:02:00-05:00,PTCT,positive
1040598.0,PTC Therapeutics To Join Russell 2000 Index,2013-09-30 08:08:00-04:00,PTCT,positive
1040599.0,"Cowen & Company Initiates Coverage on PTC Therapeutics at Outperform, Announces $33.00 PT",2013-07-26 08:08:00-04:00,PTCT,neutral
1040600.0,UPDATE: Wedbush Initiates PTC Therapeutics at Outperform on Ataluren Potential,2013-07-17 09:37:00-04:00,PTCT,neutral
1040601.0,Benzinga's Top Initiations,2013-07-17 07:43:00-04:00,PTCT,positive
1040602.0,"Wedbush Initiates Coverage on PTC Therapeutics at Outperform, Announces $55.00 PT",2013-07-17 07:25:00-04:00,PTCT,neutral
1040603.0,"Traders in PTC Therapeutics Attributing Recent Spike Higher to New Outperform Rating, $55 Target at Wedbush",2013-07-16 13:17:00-04:00,PTCT,neutral
1040604.0,UPDATE: Credit Suisse Initiates PTC Therapeutics at Outperform on Bullish Thesis,2013-07-15 09:31:00-04:00,PTCT,positive
1040605.0,UPDATE: J.P. Morgan Initiates PTC Therapeutics at Overweight on Ataluren Potential,2013-07-15 09:22:00-04:00,PTCT,negative
1040606.0,Benzinga's Top Initiations,2013-07-15 07:43:00-04:00,PTCT,positive
1040607.0,"Credit Suisse Initiates Coverage on PTC Therapeutics at Outperform, Announces $24.00 PT",2013-07-15 07:29:00-04:00,PTCT,positive
1040608.0,"JP Morgan Initiates Coverage on PTC Therapeutics at Overweight, Announces $20.00 PT",2013-07-15 06:54:00-04:00,PTCT,neutral
1040609.0,"PTC Therapeutics Opens at $15.80/Share, Priced at $15",2013-06-20 10:45:00-04:00,PTCT,neutral
1040610.0,"Shares of PTC Therapeutics Now Open for Quote, IPO Expected to Open at 10:40AM EDT",2013-06-20 10:27:00-04:00,PTCT,positive
1040611.0,PTC Therapeutics Prices 8.372M Share IPO at $15.00/Share,2013-06-20 06:20:00-04:00,PTCT,positive
1040612.0,PTC Therapeutics Sees IPO of 6.9M Shares in $13-16/Share Range,2013-06-13 16:44:00-04:00,PTCT,positive
